Pure Global AI
NCT06373744Completed

Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

Sun Yat-sen UniversityClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Breast Cancer
Drug/Device/Intervention
cyclophosphamide , methotrexate , vinorelbine ,capecitabine
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Sun Yat-sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2023
End date
Jan 01, 2024
Enrollment
597 participants
Primary outcome

Progression free survival

Summary

The goal of this observational study is to learn about the effects of metronomic chemotherapy
 in advanced breast cancer patients. The main question it aims to answer is:
 
 How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups
 of metronomic chemotherapy.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedMalignant neoplasm: Breast, unspecifiedOther carcinoma in situ of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06373744
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06373744 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-sen University and is currently Completed. The study focuses on Breast Cancer. Target enrollment is 597 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.